Peter Wung

434 citations

20 papers · 270 indexed · h-index 6

Impact in

Rheumatology top 5%
- Spondyloarthritis Studies and Treatments
- Rheumatoid Arthritis Research and Therapies
- Systemic Lupus Erythematosus Research
Hematology top 10%
- Autoimmune and Inflammatory Disorders Research

Papers in ⓘ

Rheumatology 20
- Spondyloarthritis Studies and Treatments 17
- Rheumatoid Arthritis Research and Therapies 13
- Systemic Lupus Erythematosus Research 1
Hematology 11
- Autoimmune and Inflammatory Disorders Research 11

Co-authors: In‐Ho Song (7 shared papers)Désirée van der Heijde (6 shared papers)Atul Deodhar (5 shared papers)Aileen L. Pangan (2 shared papers)Mitsumasa Kishimoto (9 shared papers)Yuanyuan Duan (3 shared papers)Walter P. Maksymowych (7 shared papers)Joachim Sieper (4 shared papers)
Journals: Annals of the Rheumatic Diseases (10 papers)Arthritis Research & Therapy (3 papers)Rheumatology and Therapy (2 papers)Clinical and Experimental Rheumatology (1 paper)The Lancet (1 paper)
Partner nations: United States Germany Japan

In The Last Decade

Peter Wung

18 papers receiving 266 citations

Peers

Countries citing papers authored by Peter Wung

Since Specialization

Citations

This map shows the geographic impact of Peter Wung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Wung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Wung more than expected).

Fields of papers citing papers by Peter Wung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Wung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Wung. The network helps show where Peter Wung may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Wung, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Wung Line = papers co-authored together Peter Wung links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial The Lancet ·Atul Deodhar, Filip Van den Bosch, Denis Poddubnyy, Walter P. Maksymowych, Désirée van der Heijde, Tae‐Hwan Kim, Mitsumasa Kishimoto, Ricardo Blanco, Yuanyuan Duan, Yihan Li, Aileen L. Pangan, Peter Wung, In‐Ho Song	2022	86
2	Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial Annals of the Rheumatic Diseases ·Désirée van der Heijde, Xenofon Baraliakos, Joachim Sieper, Atul Deodhar, Robert D. Inman, Hideto Kameda, Xiaofeng Zeng, Yunxia Sui, Xianwei Bu, Aileen L. Pangan, Peter Wung, In‐Ho Song	2022	79
3	Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension RMD Open ·Désirée van der Heijde, Atul Deodhar, Walter P. Maksymowych, Joachim Sieper, Filip Van den Bosch, Tae‐Hwan Kim, Mitsumasa Kishimoto, Andrew J.K. Östör, Bernard Combe, Yunxia Sui, Yuanyuan Duan, Peter Wung, In‐Ho Song	2022	32
4	Efficacy and Safety of Upadacitinib in Patients with Psoriatic Arthritis: 2-Year Results from the Phase 3 SELECT-PsA 1 Study Rheumatology and Therapy ·Iain B. McInnes, Koji Kato, Marina Magrey, Joseph F. Merola, Mitsumasa Kishimoto, Derek Haaland, Liang Chen, Yuanyuan Duan, Jianzhong Liu, Ralph Lippe, Peter Wung	2022	28
5	Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study Arthritis Research & Therapy ·Xenofon Baraliakos, Désirée van der Heijde, Joachim Sieper, Robert D. Inman, Hideto Kameda, Yihan Li, Xianwei Bu, Anna Shmagel, Peter Wung, In‐Ho Song, Atul Deodhar	2023	12
6	LBA0001 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH GIANT CELL ARTERITIS (SELECT-GCA): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL Annals of the Rheumatic Diseases ·Daniël Blockmans, Steven Penn, A. Setty, Wolfgang Schmidt, Andrea Rubbert‐Roth, E.M. Hauge, Helen Keen, Tomonori Ishii, Nader Khalidi, Mei Liu, Zhao Wen, I. Lagunes, Alfonso E. Romero, Peter Wung, Peter A. Merkel	2024	9
7	OP0016 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL Annals of the Rheumatic Diseases ·Atul Deodhar, F. Van den Bosch, Denis Poddubnyy, Walter P. Maksymowych, D. van der Heijde, T. H. Kim, M. Kishimoto, Y. Duan, Y. Li, A. Pangan, Peter Wung, I. H. Song	2022	4
8	Upadacitinib in Active Non‐radiographic Axial Spondyloarthritis: 1‐Year Data From a Double‐Blind, Randomized, Placebo‐Controlled, Phase 3 Trial ACR Open Rheumatology ·Filip Van den Bosch, Atul Deodhar, Denis Poddubnyy, Walter P. Maksymowych, Désirée van der Heijde, Tae‐Hwan Kim, Mitsumasa Kishimoto, Xenofon Baraliakos, Yihan Li, Kristin M. D’Silva, Peter Wung, In‐Ho Song	2024	3
9	Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2 Rheumatology and Therapy ·Uta Kiltz, Mitsumasa Kishimoto, Jessica A. Walsh, Percival D. Sampaio‐Barros, Manish Mittal, Christopher D. Saffore, Peter Wung, Fabiana Ganz, Ana Biljan, Denis Poddubnyy	2023	3
10	Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study Arthritis Research & Therapy ·Xenofon Baraliakos, Désirée van der Heijde, J. Sieper, Robert D. Inman, Hideto Kameda, Walter P. Maksymowych, I. Lagunes-Galindo, Xianwei Bu, Peter Wung, Koji Kato, Anna Shmagel, Atul Deodhar	2024	2
11	OP0061 DEVELOPMENT OF EXTRA-MUSCULOSKELETAL MANIFESTATIONS IN UPADACITINIB-TREATED PATIENTS WITH PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS, OR NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS Annals of the Rheumatic Diseases ·Denis Poddubnyy, B. Parikh, Dirk Elewaut, Victoria Navarro‐Compán, Stefan Siebert, Michael Paley, Dane Coombs, R. Mccaskill, Ana Biljan, Peter Wung, Ennio Lubrano	2023	2
12	POS0250 PLACEBO-CONTROLLED EFFICACY AND SAFETY OF UPADACITINIB THROUGH ONE YEAR IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS Annals of the Rheumatic Diseases ·Filip Van den Bosch, Atul Deodhar, Denis Poddubnyy, Walter P. Maksymowych, Désirée van der Heijde, T. H. Kim, Mitsumasa Kishimoto, Xenofon Baraliakos, Yi Duan, Kristin M. D’Silva, Peter Wung, In‐Ho Song	2023	2
13	Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study Clinical and Experimental Rheumatology ·Philip J. Mease, Arathi R. Setty, Kim Papp, Filip Van den Bosch, Shigeyoshi Tsuji, Mauro Waldemar Keiserman, Kyle Carter, Yihan Li, R. Mccaskill, E. Mcdearmon-Blondell, Peter Wung, William Tillett	2023	2
14	POS0306 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS REFRACTORY TO BIOLOGIC THERAPY: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 3 TRIAL Annals of the Rheumatic Diseases ·D. van der Heijde, Xenofon Baraliakos, J. Sieper, A. Deodhar, R. Inman, H. Kameda, X. Zeng, Y. Sui, X. Bu, A. Pangan, Peter Wung, I. H. Song	2022	2
15	POS1541 LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM THE PHASE 3 SELECT-PsA 1 STUDY Annals of the Rheumatic Diseases ·Iain B. McInnes, Koji Kato, Marina Magrey, Joseph F. Merola, Mitsumasa Kishimoto, D. Haaland, Y. LI, Yi Liu, J. Liu, Roger Lippé, Peter Wung	2023	1
16	POS1122 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE ANKYLOSING SPONDYLITIS AND AN INADEQUATE RESPONSE TO BIOLOGIC DMARD THERAPY: ONE-YEAR RESULTS FROM A PHASE 3 STUDY Annals of the Rheumatic Diseases ·Xenofon Baraliakos, D. van der Heijde, Joachim Sieper, Robert D. Inman, H. Kameda, Y. LI, X. Bu, A. Shmagel, Peter Wung, In‐Ho Song, Atul Deodhar	2023	1
17	POS1108 EFFICACY OF UPADACITINIB IN PATIENTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS IN EARLY VERSUS ESTABLISHED DISEASE V. Navarro-Compán, Filip Van den Bosch, Percival D. Sampaio‐Barros, Fabiana Ganz, Ana Biljan, Y. Duan, Kristin M. D’Silva, Peter Wung, Andrew J.K. Östör, Sofía Ramiro	2023	1
18	POS0081 LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PsA 1 STUDY Annals of the Rheumatic Diseases ·Iain B. McInnes, Koji Kato, Marina Magrey, Joseph F. Merola, Mitsumasa Kishimoto, Derek Haaland, L. Chen, Yi Duan, J. Liu, Roger Lippé, Peter Wung	2022	1
19	Upadacitinib in active non-radiographic axial spondyloarthritis: 2-year data from the phase 3 SELECT-AXIS 2 study Arthritis Research & Therapy ·Filip Van den Bosch, Atul Deodhar, Denis Poddubnyy, Walter P. Maksymowych, Désirée van der Heijde, Tae-Hwan Kim, Mitsumasa Kishimoto, Xenofon Baraliakos, Xianwei Bu, I. Lagunes-Galindo, In-Ho Song, Peter Wung, Koji Kato, Anna Shmagel	2025	0
20	OP0198 EFFICACY AND SAFETY OF ABBV-599 (ELSUBRUTINIB AND UPADACITINIB COMBINATION) AND UPADACITINIB MONOTHERAPY FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS THROUGH 104 WEEKS IN A LONG-TERM EXTENSION STUDY Annals of the Rheumatic Diseases ·Joan T. Merrill, Amit Saxena, Martin Aringer, Yoshiya Tanaka, Xiaofeng Zeng, Peter Wung, Cheng Li, Thao Doan, Shelly Kafka, David D’Cruz, Karl J. D’Silva	2025	0

About Peter Wung

Peter Wung is a scholar working on Rheumatology, Hematology, Immunology, Genetics and Pulmonary and Respiratory Medicine, having authored 20 papers that have together received 270 indexed citations. Recurring topics across this work include Spondyloarthritis Studies and Treatments (17 papers), Rheumatoid Arthritis Research and Therapies (13 papers), Autoimmune and Inflammatory Disorders Research (11 papers), Psoriasis: Treatment and Pathogenesis (10 papers), Fibromyalgia and Chronic Fatigue Syndrome Research (2 papers), Lymphoma Diagnosis and Treatment (1 paper), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (1 paper) and Systemic Lupus Erythematosus Research (1 paper). The work is most often cited by research in Rheumatology (236 citations), Hematology (121 citations), Immunology (151 citations), Dermatology (12 citations) and Oncology (24 citations). Peter Wung has collaborated with scholars based in United States, Germany and Japan. Frequent co-authors include In‐Ho Song, Désirée van der Heijde, Atul Deodhar, Aileen L. Pangan, Mitsumasa Kishimoto, Yuanyuan Duan, Walter P. Maksymowych, Joachim Sieper, Filip Van den Bosch and Yunxia Sui. Their work appears in journals such as Annals of the Rheumatic Diseases, Arthritis Research & Therapy, Rheumatology and Therapy, Clinical and Experimental Rheumatology and The Lancet.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact